Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluati

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical study evaluating MultiStem® in patients...

Related Keywords

Texas ,United States ,Texas Medical Center ,Houston ,University Of Texas ,Memorial Hermann Hospital ,Ellen Gurley ,Charless Cox Jr ,Dan Camardo ,Uthealth Neurosciences ,Technology Enterprise Consortium ,D Bradley Mcwilliams School Of Biomedical Informatics ,Corporate Communications ,Department Of Defense ,Linkedin ,Memorial Hermann Health System ,Harris Health Lyndonb Johnson Hospital ,Memorial Hermann Foundation ,Mcgovern Medical School ,Facebook ,Athersys Inc ,Uthealth Harris County Psychiatric Center ,Ut Health Services ,Robert Cizik School Of Nursing ,Twitter ,Kathrineg Mcgovern Medical School ,University Of Texas System Board Regents ,Department Of Pediatric Surgery ,Level One Trauma Center ,Accountable Care Organization ,Nasdaq ,Texas Health Science Center ,Memorial Hermann Texas Medical Center ,Medical Technology Enterprise Consortium ,Memorial Hermann ,Hermann Texas Medical Center ,Chief Executive Officer ,Cynthia Mitchell Distinguished Chair ,Glassell Family Distinguished Chair ,Pediatric Surgery ,Principal Investigator ,Texas System Board ,Health University ,Robert Cizik School ,Govern Medical School ,Mcwilliams School ,Biomedical Informatics ,Harris County Psychiatric Center ,Harris Health Lyndon ,Southeast Texas ,Greater Houston ,Memorial Hermann Surgical Hospital First Colony ,Memorial Hermann Surgical Hospital Kingwood ,Memorial Hermann Rehabilitation ,Private Securities Litigation Reform Act ,Annual Report ,